OSE Immunotherapeutics SA (OSE.PA)
EUR 7.17
(-1.38%)
EUR 7.17
(-1.38%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 27.12 Million EUR | 41.5% |
| 2022 | 19.17 Million EUR | 439.48% |
| 2021 | 3.55 Million EUR | 136.07% |
| 2020 | -9.85 Million EUR | 31.38% |
| 2019 | -14.36 Million EUR | -180.87% |
| 2018 | -5.11 Million EUR | -7.39% |
| 2017 | -4.76 Million EUR | 63.66% |
| 2016 | -13.1 Million EUR | -56.86% |
| 2015 | -8.35 Million EUR | -12565.67% |
| 2014 | 67 Thousand EUR | -92.27% |
| 2013 | 867 Thousand EUR | 34.21% |
| 2012 | 646 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -34.67 Million EUR | 0.0% |
| 2023 FY | 27.12 Million EUR | 41.5% |
| 2023 Q2 | 28.74 Million EUR | 0.0% |
| 2023 Q4 | 27.12 Million EUR | 0.0% |
| 2022 FY | 19.17 Million EUR | 439.48% |
| 2022 Q4 | 19.17 Million EUR | 0.0% |
| 2022 Q2 | 4.57 Million EUR | 0.0% |
| 2021 FY | 3.55 Million EUR | 136.07% |
| 2021 Q4 | 3.55 Million EUR | 0.0% |
| 2021 Q2 | -3.33 Million EUR | 0.0% |
| 2020 Q4 | -9.85 Million EUR | 0.0% |
| 2020 FY | -9.85 Million EUR | 31.38% |
| 2020 Q2 | -3.09 Million EUR | 0.0% |
| 2019 FY | -14.36 Million EUR | -180.87% |
| 2019 Q4 | -14.36 Million EUR | 0.0% |
| 2019 Q2 | 5.17 Million EUR | 0.0% |
| 2018 FY | -5.11 Million EUR | -7.39% |
| 2018 Q4 | -5.11 Million EUR | 0.0% |
| 2018 Q2 | -11 Million EUR | 0.0% |
| 2017 FY | -4.76 Million EUR | 63.66% |
| 2017 Q2 | -13.76 Million EUR | 0.0% |
| 2017 Q4 | -4.76 Million EUR | 0.0% |
| 2016 Q2 | -6.9 Million EUR | 0.0% |
| 2016 FY | -13.1 Million EUR | -56.86% |
| 2016 Q4 | -13.11 Million EUR | 0.0% |
| 2015 FY | -8.35 Million EUR | -12565.67% |
| 2015 Q2 | -17 Million EUR | 0.0% |
| 2015 Q4 | -8.35 Million EUR | 0.0% |
| 2014 FY | 67 Thousand EUR | -92.27% |
| 2014 Q4 | 67 Thousand EUR | 0.0% |
| 2014 Q2 | -1.58 Million EUR | 0.0% |
| 2013 Q1 | - EUR | 0.0% |
| 2013 Q3 | -280 Thousand EUR | 0.0% |
| 2013 Q4 | 867 Thousand EUR | 409.64% |
| 2013 FY | 867 Thousand EUR | 34.21% |
| 2012 FY | 646 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 3899.58% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 113.808% |
| Adocia SA | 127 Thousand EUR | -21261.417% |
| Aelis Farma SA | -16.19 Million EUR | 267.546% |
| Biophytis S.A. | 2.7 Million EUR | -903.663% |
| Advicenne S.A. | 12.17 Million EUR | -122.825% |
| genOway Société anonyme | 2.97 Million EUR | -812.522% |
| IntegraGen SA | -709.74 Thousand EUR | 3922.337% |
| Medesis Pharma S.A. | 1.15 Million EUR | -2242.321% |
| Neovacs S.A. | -237.08 Thousand EUR | 11542.635% |
| NFL Biosciences SA | -2.27 Million EUR | 1292.028% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -522.723% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 3366.398% |
| Sensorion SA | 1.37 Million EUR | -1868.406% |
| Theranexus Société Anonyme | 2.44 Million EUR | -1009.954% |
| TME Pharma N.V. | -1.07 Million EUR | 2614.272% |
| Valbiotis SA | -18.13 Million EUR | 249.562% |
| TheraVet SA | 12.78 Thousand EUR | -212093.977% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | -1144.45% |
| argenx SE | -1.83 Billion EUR | 101.477% |
| BioSenic S.A. | 28.04 Million EUR | 3.263% |
| Celyad Oncology SA | -6.1 Million EUR | 544.592% |
| DBV Technologies S.A. | -114.95 Million USD | 123.599% |
| Galapagos NV | -157.2 Million EUR | 117.257% |
| Genfit S.A. | -7.61 Million EUR | 456.445% |
| GeNeuro SA | 5.91 Million EUR | -359.004% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 208.032% |
| Innate Pharma S.A. | -30.71 Million EUR | 188.334% |
| Inventiva S.A. | 10.48 Million EUR | -158.642% |
| MaaT Pharma SA | -10.2 Million EUR | 365.84% |
| MedinCell S.A. | 39.5 Million EUR | 31.321% |
| Nanobiotix S.A. | -24.71 Million EUR | 209.754% |
| Onward Medical N.V. | -12.89 Million EUR | 310.4% |
| Oryzon Genomics S.A. | 1.43 Million EUR | -1796.69% |
| Oxurion NV | 10.71 Million EUR | -153.305% |
| Pharming Group N.V. | 99.4 Million EUR | 72.708% |
| Poxel S.A. | 44.55 Million EUR | 39.117% |
| GenSight Biologics S.A. | 16.29 Million EUR | -66.497% |
| Transgene SA | -14.4 Million EUR | 288.278% |
| Financière de Tubize SA | 78.62 Million EUR | 65.496% |
| UCB SA | 2.17 Billion EUR | 98.754% |
| Valneva SE | 82.73 Million EUR | 67.21% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 246.453% |